These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1072 related articles for article (PubMed ID: 30145359)

  • 41. Tumor CD155 Expression Is Associated with Resistance to Anti-PD1 Immunotherapy in Metastatic Melanoma.
    Lepletier A; Madore J; O'Donnell JS; Johnston RL; Li XY; McDonald E; Ahern E; Kuchel A; Eastgate M; Pearson SA; Mallardo D; Ascierto PA; Massi D; Merelli B; Mandala M; Wilmott JS; Menzies AM; Leduc C; Stagg J; Routy B; Long GV; Scolyer RA; Bald T; Waddell N; Dougall WC; Teng MWL; Smyth MJ
    Clin Cancer Res; 2020 Jul; 26(14):3671-3681. PubMed ID: 32345648
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Immunogenomics of Colorectal Cancer Response to Checkpoint Blockade: Analysis of the KEYNOTE 177 Trial and Validation Cohorts.
    Bortolomeazzi M; Keddar MR; Montorsi L; Acha-Sagredo A; Benedetti L; Temelkovski D; Choi S; Petrov N; Todd K; Wai P; Kohl J; Denner T; Nye E; Goldstone R; Ward S; Wilson GA; Al Bakir M; Swanton C; John S; Miles J; Larijani B; Kunene V; Fontana E; Arkenau HT; Parker PJ; Rodriguez-Justo M; Shiu KK; Spencer J; Ciccarelli FD
    Gastroenterology; 2021 Oct; 161(4):1179-1193. PubMed ID: 34197832
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Distinct exhaustion features of T lymphocytes shape the tumor-immune microenvironment with therapeutic implication in patients with non-small-cell lung cancer.
    Kim CG; Kim G; Kim KH; Park S; Shin S; Yeo D; Shim HS; Yoon HI; Park SY; Ha SJ; Kim HR
    J Immunother Cancer; 2021 Dec; 9(12):. PubMed ID: 34907028
    [TBL] [Abstract][Full Text] [Related]  

  • 44. A Threshold Level of Intratumor CD8+ T-cell PD1 Expression Dictates Therapeutic Response to Anti-PD1.
    Ngiow SF; Young A; Jacquelot N; Yamazaki T; Enot D; Zitvogel L; Smyth MJ
    Cancer Res; 2015 Sep; 75(18):3800-11. PubMed ID: 26208901
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Blockade of PD1 and TIM3 restores innate and adaptive immunity in patients with acute alcoholic hepatitis.
    Markwick LJ; Riva A; Ryan JM; Cooksley H; Palma E; Tranah TH; Manakkat Vijay GK; Vergis N; Thursz M; Evans A; Wright G; Tarff S; O'Grady J; Williams R; Shawcross DL; Chokshi S
    Gastroenterology; 2015 Mar; 148(3):590-602.e10. PubMed ID: 25479137
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Differences between exhausted CD8
    Xiaohong C; Jianzhou Z; Bo S; Wenlv L; Xuesen C; Fangfang X
    Can J Physiol Pharmacol; 2021 Apr; 99(4):395-401. PubMed ID: 32799654
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Exhausted phenotype of circulating CD8
    Jiang D; Chen C; Yan D; Zhang X; Liu X; Yan D; Cui D; Yang S
    BMC Immunol; 2022 Apr; 23(1):18. PubMed ID: 35443611
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Non-terminally exhausted tumor-resident memory HBV-specific T cell responses correlate with relapse-free survival in hepatocellular carcinoma.
    Cheng Y; Gunasegaran B; Singh HD; Dutertre CA; Loh CY; Lim JQ; Crawford JC; Lee HK; Zhang X; Lee B; Becht E; Lim WJ; Yeong J; Chan CY; Chung A; Goh BKP; Chow PKH; Chan JKY; Ginhoux F; Tai D; Chen J; Lim SG; Zhai W; Choo SP; Newell EW
    Immunity; 2021 Aug; 54(8):1825-1840.e7. PubMed ID: 34270940
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Immunogenomic landscape of hepatocellular carcinoma with immune cell stroma and EBV-positive tumor-infiltrating lymphocytes.
    Kang HJ; Oh JH; Chun SM; Kim D; Ryu YM; Hwang HS; Kim SY; An J; Cho EJ; Lee H; Shim JH; Sung CO; Yu E
    J Hepatol; 2019 Jul; 71(1):91-103. PubMed ID: 30930222
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Regorafenib combined with PD1 blockade increases CD8 T-cell infiltration by inducing CXCL10 expression in hepatocellular carcinoma.
    Shigeta K; Matsui A; Kikuchi H; Klein S; Mamessier E; Chen IX; Aoki S; Kitahara S; Inoue K; Shigeta A; Hato T; Ramjiawan RR; Staiculescu D; Zopf D; Fiebig L; Hobbs GS; Quaas A; Dima S; Popescu I; Huang P; Munn LL; Cobbold M; Goyal L; Zhu AX; Jain RK; Duda DG
    J Immunother Cancer; 2020 Nov; 8(2):. PubMed ID: 33234602
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Kupffer cell suppression of CD8+ T cells in human hepatocellular carcinoma is mediated by B7-H1/programmed death-1 interactions.
    Wu K; Kryczek I; Chen L; Zou W; Welling TH
    Cancer Res; 2009 Oct; 69(20):8067-75. PubMed ID: 19826049
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Immune-Checkpoint Blockade Opposes CD8
    Pfannenstiel LW; Diaz-Montero CM; Tian YF; Scharpf J; Ko JS; Gastman BR
    Cancer Immunol Res; 2019 Mar; 7(3):510-525. PubMed ID: 30728151
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Functional CD3
    Lv S; Wang S; Qiao G; Wang X; Zhou X; Yan F; Li Y; Wang S; Morse MA; Hobeika A; Ren J; Lyerly HK
    Clin Breast Cancer; 2019 Oct; 19(5):e617-e623. PubMed ID: 31101455
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Using mouse liver cancer models based on somatic genome editing to predict immune checkpoint inhibitor responses.
    Yuen VW; Chiu DK; Law CT; Cheu JW; Chan CY; Wong BP; Goh CC; Zhang MS; Xue HD; Tse AP; Zhang Y; Lau HY; Lee D; Au-Yeung RKH; Wong CM; Wong CC
    J Hepatol; 2023 Feb; 78(2):376-389. PubMed ID: 36455783
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Interaction of Breast Cancer and Insulin Resistance on PD1 and TIM3 Expression in Peripheral Blood CD8 T Cells.
    Martín-Manzo MV; Lara C; Vargas-de-Leon C; Carrero J; Queipo G; Fonseca-Sanchez M; Mejia-Dominguez NR; Kershenobich D; Mummidi S; Zentella-Dehesa A; Hernandez J
    Pathol Oncol Res; 2019 Jul; 25(3):1233-1243. PubMed ID: 30759303
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Intratumoral CD3 and CD8 T-cell Densities Associated with Relapse-Free Survival in HCC.
    Gabrielson A; Wu Y; Wang H; Jiang J; Kallakury B; Gatalica Z; Reddy S; Kleiner D; Fishbein T; Johnson L; Island E; Satoskar R; Banovac F; Jha R; Kachhela J; Feng P; Zhang T; Tesfaye A; Prins P; Loffredo C; Marshall J; Weiner L; Atkins M; He AR
    Cancer Immunol Res; 2016 May; 4(5):419-30. PubMed ID: 26968206
    [TBL] [Abstract][Full Text] [Related]  

  • 57. The CD39
    Zou F; Tan J; Liu T; Liu B; Tang Y; Zhang H; Li J
    Mol Ther; 2021 May; 29(5):1794-1807. PubMed ID: 33484968
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Immune checkpoint proteins PD-1 and TIM-3 are both highly expressed in liver tissues and correlate with their gene polymorphisms in patients with HBV-related hepatocellular carcinoma.
    Li Z; Li N; Li F; Zhou Z; Sang J; Chen Y; Han Q; Lv Y; Liu Z
    Medicine (Baltimore); 2016 Dec; 95(52):e5749. PubMed ID: 28033288
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Immune Checkpoint Inhibitor-induced Reinvigoration of Tumor-infiltrating CD8
    Park J; Kwon M; Kim KH; Kim TS; Hong SH; Kim CG; Kang SG; Moon JH; Kim EH; Park SH; Chang JH; Shin EC
    Clin Cancer Res; 2019 Apr; 25(8):2549-2559. PubMed ID: 30659023
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Interleukin-35 has a tumor-promoting role in hepatocellular carcinoma.
    Liu X; Ren H; Guo H; Wang W; Zhao N
    Clin Exp Immunol; 2021 Feb; 203(2):219-229. PubMed ID: 33030251
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 54.